Decoding biology to engineer the next medicines.
A translational bioplatform pairing predictive models with patient-derived assays, carrying programs from target to clinic with unprecedented speed.
We work where biology
is hardest, and bring back
candidates that translate.
Approach
Most discovery pipelines optimise for hits in a dish. Translation to humans is left as a downstream problem — one that quietly kills 90% of programs in Phase 2. Unobio inverts the order. We start every program from patient data and run computational, experimental, and clinical layers in lockstep, so by the time a candidate reaches IND, it has already been pressure-tested against the biology that matters.
Two operational layers, one platform.
Computational biology
Foundation models trained on 1.2B annotated biological sequences predict protein–compound interactions in silico, surfacing leads weeks ahead of physical assay. The graph is updated nightly with every new wet-lab readout.
Translational clinical
A biomarker-led clinical team carries promising candidates through IND-enabling studies and Phase 1 in partnership with academic medical centers across three continents.
By the numbers.
Real-world data points continuously tracked across the platform.
Faster deal search, evaluation, and execution end-to-end.
More qualified opportunities identified vs. legacy workflows.
Become a partner.
We partner with pharma, foundation, and venture-backed programs on co-developed discovery and translational work. New engagements typically begin with a two-week feasibility sprint.